To identify a set of biomarkers suitable for monitoring progression of IBD to CRC, RUNX1 was further tested in combination with four known CRC biomarkers (CEA, TIMP1, CA724, CA199). This evidence concerns the gene CEACAM5 and inflammatory bowel disease.